January 22, 2008

Daniel J. Rader, MD, director of Penn’s Preventive Cardiovascular Medicine and Lipid Clinic, comments in the New York Times about interpreting results from the recent Vytorin® study.

The Vytorin disappointment does not “mean the whole concept is wrong,” said Rader. “I firmly believe lowering cholesterol is the most validated, most important way we can reduce our risk of heart disease and stroke. Get your LDL down, and the lower the better.”

Read the Article

January 15, 2008

Helene Glassberg, MD, assistant professor of cardiovascular medicine, comments in the Philadelphia Inquirer about the studies comparing cholesterol drugs, Zetia®, Vytorin® and Zocor®.

Read the Article

Dr. Glassberg was also quoted in an NBC 10 story about the new study comparing cholesterol-lowering drugs Zetia, Vytorin, and Zocor. She urged patients to speak with their doctors and stay the course with their current medications until further research examining a broader group of patients is published.

Read the Article

December 20, 2007

Lee Goldberg, MD, MPH, associate medical director of the heart failure/transplant program, was interviewed in a CBS 3 story about a patient with restrictive cardiomyopathy awaiting a heart transplant at Hospital of the University of Pennsylvania during the holidays.

Susan Mitchell, a patient of Joyce Wald, DO, is a young attorney whose heart condition was misdiagnosed 10 years ago at age 18. It wasn’t until last summer, when she came to Penn for the first time that she received the correct diagnosis.

Read the Article

November 26, 2007

Daniel J. Rader, MD was quoted in Philadelphia Magazine about lowering cholesterol.

Read the article